Table 2.
Best overall response, based on RECIST 1.1 criteria, according to palliative treatment in patients with HER2-positive metastatic breast cancer.
| All patients | HR+/HER2+ | HR−/HER2+ | |||||||
|---|---|---|---|---|---|---|---|---|---|
| RTZ (n=65) | CT-P6 (n=38) | P-value | RTZ (n=29) | CT-P6 (n=16) | P-value | RTZ (n=36) | CT-P6 (n=22) | P-value | |
| Overall response | 0.706 a | 0.902 a | 0.389 a | ||||||
| CR, n (%) | 5 (7.7) | 2 (5.3) | 3 (10.3) | 1 (6.3) | 2 (5.6) | 1 (4.5) | |||
| PR, n (%) | 49 (75.4) | 28 (73.7) | 18 (62.1) | 11 (68.8) | 31 (86.1) | 17 (77.3) | |||
| SD, n (%) | 7 (10.8) | 6 (15.8) | 5 (17.2) | 4 (25.0) | 2 (5.6) | 2 (9.1) | |||
| PD, n (%) | 2 (3.1) | 2 (5.3) | 2 (6.9) | 0 | 0 | 2 (9.1) | |||
| NA, n (%) | 2 (3.1) | 0 | 1 (3.4) | 0 | 1 (2.8) | 0 | |||
| Overall response rate | 0.602 | >0.999 a | 0.409 a | ||||||
| CR/PR, n (%) | 54 (83.1) | 30 (78.9) | 21 (72.4) | 12 (75.0) | 33 (91.7) | 18 (81.8) | |||
| Disease control rate | >0.999 a | 0.542 a | 0.551 a | ||||||
| CR/PR/SD, n (%) | 61 (93.8) | 36 (94.7) | 26 (89.7) | 16 (100.0) | 35 (97.2) | 20 (90.9) | |||
a
Fisher’s exact test.
CR, complete response; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NA, not available; PD, progressive disease; PR, partial response; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1; RTZ, reference trastuzumab; SD, stable disease.